De Sanctis R, et al. - On a real-world population of metastatic breast cancer (MBC) patients, researchers examined the activity and safety of eribulin, tried to find possible predictive factors for progression-free survival (PFS) and objective response via retrospectively analyzing 71 eribulin-treated MBC patients. They assessed the best response rate, PFS, and adverse events in this analysis. Findings revealed that activity and safety profiles of eribulin were consistent with literature data in this “real-world” experience. Predictive factors of PFS were performance status and number of metastatic sites. Among MBC patients, discriminant function analysis could be a promising tool to discriminate responses to eribulin.